51
|
Paraiso-Medina S, Perez-Rey D, Bucur A, Claerhout B, Alonso-Calvo R. Semantic Normalization and Query Abstraction Based on SNOMED-CT and HL7: Supporting Multicentric Clinical Trials. IEEE J Biomed Health Inform 2014; 19:1061-7. [PMID: 25248204 DOI: 10.1109/jbhi.2014.2357025] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Advances in the use of omic data and other biomarkers are increasing the number of variables in clinical research. Additional data have stratified the population of patients and require that current studies be performed among multiple institutions. Semantic interoperability and standardized data representation are a crucial task in the management of modern clinical trials. In the past few years, different efforts have focused on integrating biomedical information. Due to the complexity of this domain and the specific requirements of clinical research, the majority of data integration tasks are still performed manually. This paper presents a semantic normalization process and a query abstraction mechanism to facilitate data integration and retrieval. A process based on well-established standards from the biomedical domain and the latest semantic web technologies has been developed. Methods proposed in this paper have been tested within the EURECA EU research project, where clinical scenarios require the extraction of semantic knowledge from biomedical vocabularies. The aim of this paper is to provide a novel method to abstract from the data model and query syntax. The proposed approach has been compared with other initiatives in the field by storing the same dataset with each of those solutions. Results show an extended functionality and query capabilities at the cost of slightly worse performance in query execution. Implementations in real settings have shown that following this approach, usable interfaces can be developed to exploit clinical trial data outcomes.
Collapse
|
52
|
Tonorezos ES, Henderson TO. Clinical Guidelines for the Care of Childhood Cancer Survivors. CHILDREN-BASEL 2014; 1:227-40. [PMID: 27417477 PMCID: PMC4928728 DOI: 10.3390/children1020227] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/30/2014] [Revised: 08/26/2014] [Accepted: 09/02/2014] [Indexed: 12/13/2022]
Abstract
The Long-Term Follow-Up Guidelines for survivors of childhood, adolescent, and young adult cancers are evidence- and consensus-based guidelines that have been developed and published by the Children's Oncology Group (COG) Late Effects Committee, Nursing Discipline, and the Patient Advocacy Committee. Originally published in 2004, the guidelines are currently in version 3.0. While the COG guidelines have been praised as a model for providing risk-based survivorship care, adherence has not been uniform. Reasons for this gap include unawareness on the part of the survivor and/or care team as well as disagreement about the individual recommendations. In some cases, the burden of testing (such as annual echocardiography or repeat pulmonary function testing) may be too great. A small number of intervention studies have documented improved adherence to guideline recommendations with dissemination of informational material. Future studies should focus on individualizing screening recommendations, as well as identifying unnecessary testing.
Collapse
Affiliation(s)
- Emily S Tonorezos
- Departments of Medicine, Memorial Sloan Kettering and Weill Cornell Medical College, 300 East 66th Street, New York, NY 10065, USA.
| | - Tara O Henderson
- University of Chicago Medicine Comer Children's Hospital, 5841 S. Maryland Avenue, MC 4060, Chicago, IL 60637, USA.
| |
Collapse
|
53
|
Abstract
In the USA, approximately 26,000 adolescents and young adults (AYAs) aged 15-29 years are diagnosed with cancer every year. The cure rate among this population exceeds 80%, resulting in a growing number of AYA cancer survivors. AYA cancer survivors suffer from a wide range of long-term treatment-related toxicities that adversely affect quality of life and increase the risk of premature death. Therefore, it is important to recognize the unique medical needs of the AYA cancer survivors and develop a cost-effective and systemic approach to screen and prevent cancer treatment-related sequelae and the adverse health outcomes.
Collapse
Affiliation(s)
- Ashwin Kishtagari
- Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, N.Y., USA
| | | | | |
Collapse
|
54
|
Moskowitz CS, Chou JF, Wolden SL, Bernstein JL, Malhotra J, Novetsky Friedman D, Mubdi NZ, Leisenring WM, Stovall M, Hammond S, Smith SA, Henderson TO, Boice JD, Hudson MM, Diller LR, Bhatia S, Kenney LB, Neglia JP, Begg CB, Robison LL, Oeffinger KC. Breast cancer after chest radiation therapy for childhood cancer. J Clin Oncol 2014; 32:2217-23. [PMID: 24752044 PMCID: PMC4100937 DOI: 10.1200/jco.2013.54.4601] [Citation(s) in RCA: 193] [Impact Index Per Article: 19.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE The risk of breast cancer is high in women treated for a childhood cancer with chest irradiation. We sought to examine variations in risk resulting from irradiation field and radiation dose. PATIENTS AND METHODS We evaluated cumulative breast cancer risk in 1,230 female childhood cancer survivors treated with chest irradiation who were participants in the CCSS (Childhood Cancer Survivor Study). RESULTS Childhood cancer survivors treated with lower delivered doses of radiation (median, 14 Gy; range, 2 to 20 Gy) to a large volume (whole-lung field) had a high risk of breast cancer (standardized incidence ratio [SIR], 43.6; 95% CI, 27.2 to 70.3), as did survivors treated with high doses of delivered radiation (median, 40 Gy) to the mantle field (SIR, 24.2; 95% CI, 20.7 to 28.3). The cumulative incidence of breast cancer by age 50 years was 30% (95% CI, 25 to 34), with a 35% incidence among Hodgkin lymphoma survivors (95% CI, 29 to 40). Breast cancer-specific mortality at 5 and 10 years was 12% (95% CI, 8 to 18) and 19% (95% CI, 13 to 25), respectively. CONCLUSION Among women treated for childhood cancer with chest radiation therapy, those treated with whole-lung irradiation have a greater risk of breast cancer than previously recognized, demonstrating the importance of radiation volume. Importantly, mortality associated with breast cancer after childhood cancer is substantial.
Collapse
Affiliation(s)
- Chaya S Moskowitz
- Chaya S. Moskowitz, Joanne F. Chou, Suzanne L. Wolden, Jonine L. Bernstein, Danielle Novetsky Friedman, Nidha Z. Mubdi, Colin B. Begg, and Kevin C. Oeffinger, Memorial Sloan Kettering Cancer Center; Jyoti Malhotra, Mount Sinai Medical Center, New York, NY; Wendy M. Leisenring, Fred Hutchinson Cancer Research Center, Seattle, WA; Marilyn Stovall and Susan A. Smith, University of Texas MD Anderson Cancer Center, Houston, TX; Sue Hammond, Nationwide Children's Hospital, Columbus, OH; Tara O. Henderson, University of Chicago Medicine Comer Children's Hospital, Chicago, IL; John D. Boice, Vanderbilt-Ingram Cancer Center, Nashville; Melissa M. Hudson and Leslie L. Robison, St Jude Children's Research Hospital, Memphis, TN; Lisa R. Diller and Lisa B. Kenney, Dana-Farber Cancer Institute, Boston, MA; Smita Bhatia, City of Hope National Medical Center, Duarte, CA; and Joseph P. Neglia, University of Minnesota Masonic Cancer Center, Minneapolis, MN.
| | - Joanne F Chou
- Chaya S. Moskowitz, Joanne F. Chou, Suzanne L. Wolden, Jonine L. Bernstein, Danielle Novetsky Friedman, Nidha Z. Mubdi, Colin B. Begg, and Kevin C. Oeffinger, Memorial Sloan Kettering Cancer Center; Jyoti Malhotra, Mount Sinai Medical Center, New York, NY; Wendy M. Leisenring, Fred Hutchinson Cancer Research Center, Seattle, WA; Marilyn Stovall and Susan A. Smith, University of Texas MD Anderson Cancer Center, Houston, TX; Sue Hammond, Nationwide Children's Hospital, Columbus, OH; Tara O. Henderson, University of Chicago Medicine Comer Children's Hospital, Chicago, IL; John D. Boice, Vanderbilt-Ingram Cancer Center, Nashville; Melissa M. Hudson and Leslie L. Robison, St Jude Children's Research Hospital, Memphis, TN; Lisa R. Diller and Lisa B. Kenney, Dana-Farber Cancer Institute, Boston, MA; Smita Bhatia, City of Hope National Medical Center, Duarte, CA; and Joseph P. Neglia, University of Minnesota Masonic Cancer Center, Minneapolis, MN
| | - Suzanne L Wolden
- Chaya S. Moskowitz, Joanne F. Chou, Suzanne L. Wolden, Jonine L. Bernstein, Danielle Novetsky Friedman, Nidha Z. Mubdi, Colin B. Begg, and Kevin C. Oeffinger, Memorial Sloan Kettering Cancer Center; Jyoti Malhotra, Mount Sinai Medical Center, New York, NY; Wendy M. Leisenring, Fred Hutchinson Cancer Research Center, Seattle, WA; Marilyn Stovall and Susan A. Smith, University of Texas MD Anderson Cancer Center, Houston, TX; Sue Hammond, Nationwide Children's Hospital, Columbus, OH; Tara O. Henderson, University of Chicago Medicine Comer Children's Hospital, Chicago, IL; John D. Boice, Vanderbilt-Ingram Cancer Center, Nashville; Melissa M. Hudson and Leslie L. Robison, St Jude Children's Research Hospital, Memphis, TN; Lisa R. Diller and Lisa B. Kenney, Dana-Farber Cancer Institute, Boston, MA; Smita Bhatia, City of Hope National Medical Center, Duarte, CA; and Joseph P. Neglia, University of Minnesota Masonic Cancer Center, Minneapolis, MN
| | - Jonine L Bernstein
- Chaya S. Moskowitz, Joanne F. Chou, Suzanne L. Wolden, Jonine L. Bernstein, Danielle Novetsky Friedman, Nidha Z. Mubdi, Colin B. Begg, and Kevin C. Oeffinger, Memorial Sloan Kettering Cancer Center; Jyoti Malhotra, Mount Sinai Medical Center, New York, NY; Wendy M. Leisenring, Fred Hutchinson Cancer Research Center, Seattle, WA; Marilyn Stovall and Susan A. Smith, University of Texas MD Anderson Cancer Center, Houston, TX; Sue Hammond, Nationwide Children's Hospital, Columbus, OH; Tara O. Henderson, University of Chicago Medicine Comer Children's Hospital, Chicago, IL; John D. Boice, Vanderbilt-Ingram Cancer Center, Nashville; Melissa M. Hudson and Leslie L. Robison, St Jude Children's Research Hospital, Memphis, TN; Lisa R. Diller and Lisa B. Kenney, Dana-Farber Cancer Institute, Boston, MA; Smita Bhatia, City of Hope National Medical Center, Duarte, CA; and Joseph P. Neglia, University of Minnesota Masonic Cancer Center, Minneapolis, MN
| | - Jyoti Malhotra
- Chaya S. Moskowitz, Joanne F. Chou, Suzanne L. Wolden, Jonine L. Bernstein, Danielle Novetsky Friedman, Nidha Z. Mubdi, Colin B. Begg, and Kevin C. Oeffinger, Memorial Sloan Kettering Cancer Center; Jyoti Malhotra, Mount Sinai Medical Center, New York, NY; Wendy M. Leisenring, Fred Hutchinson Cancer Research Center, Seattle, WA; Marilyn Stovall and Susan A. Smith, University of Texas MD Anderson Cancer Center, Houston, TX; Sue Hammond, Nationwide Children's Hospital, Columbus, OH; Tara O. Henderson, University of Chicago Medicine Comer Children's Hospital, Chicago, IL; John D. Boice, Vanderbilt-Ingram Cancer Center, Nashville; Melissa M. Hudson and Leslie L. Robison, St Jude Children's Research Hospital, Memphis, TN; Lisa R. Diller and Lisa B. Kenney, Dana-Farber Cancer Institute, Boston, MA; Smita Bhatia, City of Hope National Medical Center, Duarte, CA; and Joseph P. Neglia, University of Minnesota Masonic Cancer Center, Minneapolis, MN
| | - Danielle Novetsky Friedman
- Chaya S. Moskowitz, Joanne F. Chou, Suzanne L. Wolden, Jonine L. Bernstein, Danielle Novetsky Friedman, Nidha Z. Mubdi, Colin B. Begg, and Kevin C. Oeffinger, Memorial Sloan Kettering Cancer Center; Jyoti Malhotra, Mount Sinai Medical Center, New York, NY; Wendy M. Leisenring, Fred Hutchinson Cancer Research Center, Seattle, WA; Marilyn Stovall and Susan A. Smith, University of Texas MD Anderson Cancer Center, Houston, TX; Sue Hammond, Nationwide Children's Hospital, Columbus, OH; Tara O. Henderson, University of Chicago Medicine Comer Children's Hospital, Chicago, IL; John D. Boice, Vanderbilt-Ingram Cancer Center, Nashville; Melissa M. Hudson and Leslie L. Robison, St Jude Children's Research Hospital, Memphis, TN; Lisa R. Diller and Lisa B. Kenney, Dana-Farber Cancer Institute, Boston, MA; Smita Bhatia, City of Hope National Medical Center, Duarte, CA; and Joseph P. Neglia, University of Minnesota Masonic Cancer Center, Minneapolis, MN
| | - Nidha Z Mubdi
- Chaya S. Moskowitz, Joanne F. Chou, Suzanne L. Wolden, Jonine L. Bernstein, Danielle Novetsky Friedman, Nidha Z. Mubdi, Colin B. Begg, and Kevin C. Oeffinger, Memorial Sloan Kettering Cancer Center; Jyoti Malhotra, Mount Sinai Medical Center, New York, NY; Wendy M. Leisenring, Fred Hutchinson Cancer Research Center, Seattle, WA; Marilyn Stovall and Susan A. Smith, University of Texas MD Anderson Cancer Center, Houston, TX; Sue Hammond, Nationwide Children's Hospital, Columbus, OH; Tara O. Henderson, University of Chicago Medicine Comer Children's Hospital, Chicago, IL; John D. Boice, Vanderbilt-Ingram Cancer Center, Nashville; Melissa M. Hudson and Leslie L. Robison, St Jude Children's Research Hospital, Memphis, TN; Lisa R. Diller and Lisa B. Kenney, Dana-Farber Cancer Institute, Boston, MA; Smita Bhatia, City of Hope National Medical Center, Duarte, CA; and Joseph P. Neglia, University of Minnesota Masonic Cancer Center, Minneapolis, MN
| | - Wendy M Leisenring
- Chaya S. Moskowitz, Joanne F. Chou, Suzanne L. Wolden, Jonine L. Bernstein, Danielle Novetsky Friedman, Nidha Z. Mubdi, Colin B. Begg, and Kevin C. Oeffinger, Memorial Sloan Kettering Cancer Center; Jyoti Malhotra, Mount Sinai Medical Center, New York, NY; Wendy M. Leisenring, Fred Hutchinson Cancer Research Center, Seattle, WA; Marilyn Stovall and Susan A. Smith, University of Texas MD Anderson Cancer Center, Houston, TX; Sue Hammond, Nationwide Children's Hospital, Columbus, OH; Tara O. Henderson, University of Chicago Medicine Comer Children's Hospital, Chicago, IL; John D. Boice, Vanderbilt-Ingram Cancer Center, Nashville; Melissa M. Hudson and Leslie L. Robison, St Jude Children's Research Hospital, Memphis, TN; Lisa R. Diller and Lisa B. Kenney, Dana-Farber Cancer Institute, Boston, MA; Smita Bhatia, City of Hope National Medical Center, Duarte, CA; and Joseph P. Neglia, University of Minnesota Masonic Cancer Center, Minneapolis, MN
| | - Marilyn Stovall
- Chaya S. Moskowitz, Joanne F. Chou, Suzanne L. Wolden, Jonine L. Bernstein, Danielle Novetsky Friedman, Nidha Z. Mubdi, Colin B. Begg, and Kevin C. Oeffinger, Memorial Sloan Kettering Cancer Center; Jyoti Malhotra, Mount Sinai Medical Center, New York, NY; Wendy M. Leisenring, Fred Hutchinson Cancer Research Center, Seattle, WA; Marilyn Stovall and Susan A. Smith, University of Texas MD Anderson Cancer Center, Houston, TX; Sue Hammond, Nationwide Children's Hospital, Columbus, OH; Tara O. Henderson, University of Chicago Medicine Comer Children's Hospital, Chicago, IL; John D. Boice, Vanderbilt-Ingram Cancer Center, Nashville; Melissa M. Hudson and Leslie L. Robison, St Jude Children's Research Hospital, Memphis, TN; Lisa R. Diller and Lisa B. Kenney, Dana-Farber Cancer Institute, Boston, MA; Smita Bhatia, City of Hope National Medical Center, Duarte, CA; and Joseph P. Neglia, University of Minnesota Masonic Cancer Center, Minneapolis, MN
| | - Sue Hammond
- Chaya S. Moskowitz, Joanne F. Chou, Suzanne L. Wolden, Jonine L. Bernstein, Danielle Novetsky Friedman, Nidha Z. Mubdi, Colin B. Begg, and Kevin C. Oeffinger, Memorial Sloan Kettering Cancer Center; Jyoti Malhotra, Mount Sinai Medical Center, New York, NY; Wendy M. Leisenring, Fred Hutchinson Cancer Research Center, Seattle, WA; Marilyn Stovall and Susan A. Smith, University of Texas MD Anderson Cancer Center, Houston, TX; Sue Hammond, Nationwide Children's Hospital, Columbus, OH; Tara O. Henderson, University of Chicago Medicine Comer Children's Hospital, Chicago, IL; John D. Boice, Vanderbilt-Ingram Cancer Center, Nashville; Melissa M. Hudson and Leslie L. Robison, St Jude Children's Research Hospital, Memphis, TN; Lisa R. Diller and Lisa B. Kenney, Dana-Farber Cancer Institute, Boston, MA; Smita Bhatia, City of Hope National Medical Center, Duarte, CA; and Joseph P. Neglia, University of Minnesota Masonic Cancer Center, Minneapolis, MN
| | - Susan A Smith
- Chaya S. Moskowitz, Joanne F. Chou, Suzanne L. Wolden, Jonine L. Bernstein, Danielle Novetsky Friedman, Nidha Z. Mubdi, Colin B. Begg, and Kevin C. Oeffinger, Memorial Sloan Kettering Cancer Center; Jyoti Malhotra, Mount Sinai Medical Center, New York, NY; Wendy M. Leisenring, Fred Hutchinson Cancer Research Center, Seattle, WA; Marilyn Stovall and Susan A. Smith, University of Texas MD Anderson Cancer Center, Houston, TX; Sue Hammond, Nationwide Children's Hospital, Columbus, OH; Tara O. Henderson, University of Chicago Medicine Comer Children's Hospital, Chicago, IL; John D. Boice, Vanderbilt-Ingram Cancer Center, Nashville; Melissa M. Hudson and Leslie L. Robison, St Jude Children's Research Hospital, Memphis, TN; Lisa R. Diller and Lisa B. Kenney, Dana-Farber Cancer Institute, Boston, MA; Smita Bhatia, City of Hope National Medical Center, Duarte, CA; and Joseph P. Neglia, University of Minnesota Masonic Cancer Center, Minneapolis, MN
| | - Tara O Henderson
- Chaya S. Moskowitz, Joanne F. Chou, Suzanne L. Wolden, Jonine L. Bernstein, Danielle Novetsky Friedman, Nidha Z. Mubdi, Colin B. Begg, and Kevin C. Oeffinger, Memorial Sloan Kettering Cancer Center; Jyoti Malhotra, Mount Sinai Medical Center, New York, NY; Wendy M. Leisenring, Fred Hutchinson Cancer Research Center, Seattle, WA; Marilyn Stovall and Susan A. Smith, University of Texas MD Anderson Cancer Center, Houston, TX; Sue Hammond, Nationwide Children's Hospital, Columbus, OH; Tara O. Henderson, University of Chicago Medicine Comer Children's Hospital, Chicago, IL; John D. Boice, Vanderbilt-Ingram Cancer Center, Nashville; Melissa M. Hudson and Leslie L. Robison, St Jude Children's Research Hospital, Memphis, TN; Lisa R. Diller and Lisa B. Kenney, Dana-Farber Cancer Institute, Boston, MA; Smita Bhatia, City of Hope National Medical Center, Duarte, CA; and Joseph P. Neglia, University of Minnesota Masonic Cancer Center, Minneapolis, MN
| | - John D Boice
- Chaya S. Moskowitz, Joanne F. Chou, Suzanne L. Wolden, Jonine L. Bernstein, Danielle Novetsky Friedman, Nidha Z. Mubdi, Colin B. Begg, and Kevin C. Oeffinger, Memorial Sloan Kettering Cancer Center; Jyoti Malhotra, Mount Sinai Medical Center, New York, NY; Wendy M. Leisenring, Fred Hutchinson Cancer Research Center, Seattle, WA; Marilyn Stovall and Susan A. Smith, University of Texas MD Anderson Cancer Center, Houston, TX; Sue Hammond, Nationwide Children's Hospital, Columbus, OH; Tara O. Henderson, University of Chicago Medicine Comer Children's Hospital, Chicago, IL; John D. Boice, Vanderbilt-Ingram Cancer Center, Nashville; Melissa M. Hudson and Leslie L. Robison, St Jude Children's Research Hospital, Memphis, TN; Lisa R. Diller and Lisa B. Kenney, Dana-Farber Cancer Institute, Boston, MA; Smita Bhatia, City of Hope National Medical Center, Duarte, CA; and Joseph P. Neglia, University of Minnesota Masonic Cancer Center, Minneapolis, MN
| | - Melissa M Hudson
- Chaya S. Moskowitz, Joanne F. Chou, Suzanne L. Wolden, Jonine L. Bernstein, Danielle Novetsky Friedman, Nidha Z. Mubdi, Colin B. Begg, and Kevin C. Oeffinger, Memorial Sloan Kettering Cancer Center; Jyoti Malhotra, Mount Sinai Medical Center, New York, NY; Wendy M. Leisenring, Fred Hutchinson Cancer Research Center, Seattle, WA; Marilyn Stovall and Susan A. Smith, University of Texas MD Anderson Cancer Center, Houston, TX; Sue Hammond, Nationwide Children's Hospital, Columbus, OH; Tara O. Henderson, University of Chicago Medicine Comer Children's Hospital, Chicago, IL; John D. Boice, Vanderbilt-Ingram Cancer Center, Nashville; Melissa M. Hudson and Leslie L. Robison, St Jude Children's Research Hospital, Memphis, TN; Lisa R. Diller and Lisa B. Kenney, Dana-Farber Cancer Institute, Boston, MA; Smita Bhatia, City of Hope National Medical Center, Duarte, CA; and Joseph P. Neglia, University of Minnesota Masonic Cancer Center, Minneapolis, MN
| | - Lisa R Diller
- Chaya S. Moskowitz, Joanne F. Chou, Suzanne L. Wolden, Jonine L. Bernstein, Danielle Novetsky Friedman, Nidha Z. Mubdi, Colin B. Begg, and Kevin C. Oeffinger, Memorial Sloan Kettering Cancer Center; Jyoti Malhotra, Mount Sinai Medical Center, New York, NY; Wendy M. Leisenring, Fred Hutchinson Cancer Research Center, Seattle, WA; Marilyn Stovall and Susan A. Smith, University of Texas MD Anderson Cancer Center, Houston, TX; Sue Hammond, Nationwide Children's Hospital, Columbus, OH; Tara O. Henderson, University of Chicago Medicine Comer Children's Hospital, Chicago, IL; John D. Boice, Vanderbilt-Ingram Cancer Center, Nashville; Melissa M. Hudson and Leslie L. Robison, St Jude Children's Research Hospital, Memphis, TN; Lisa R. Diller and Lisa B. Kenney, Dana-Farber Cancer Institute, Boston, MA; Smita Bhatia, City of Hope National Medical Center, Duarte, CA; and Joseph P. Neglia, University of Minnesota Masonic Cancer Center, Minneapolis, MN
| | - Smita Bhatia
- Chaya S. Moskowitz, Joanne F. Chou, Suzanne L. Wolden, Jonine L. Bernstein, Danielle Novetsky Friedman, Nidha Z. Mubdi, Colin B. Begg, and Kevin C. Oeffinger, Memorial Sloan Kettering Cancer Center; Jyoti Malhotra, Mount Sinai Medical Center, New York, NY; Wendy M. Leisenring, Fred Hutchinson Cancer Research Center, Seattle, WA; Marilyn Stovall and Susan A. Smith, University of Texas MD Anderson Cancer Center, Houston, TX; Sue Hammond, Nationwide Children's Hospital, Columbus, OH; Tara O. Henderson, University of Chicago Medicine Comer Children's Hospital, Chicago, IL; John D. Boice, Vanderbilt-Ingram Cancer Center, Nashville; Melissa M. Hudson and Leslie L. Robison, St Jude Children's Research Hospital, Memphis, TN; Lisa R. Diller and Lisa B. Kenney, Dana-Farber Cancer Institute, Boston, MA; Smita Bhatia, City of Hope National Medical Center, Duarte, CA; and Joseph P. Neglia, University of Minnesota Masonic Cancer Center, Minneapolis, MN
| | - Lisa B Kenney
- Chaya S. Moskowitz, Joanne F. Chou, Suzanne L. Wolden, Jonine L. Bernstein, Danielle Novetsky Friedman, Nidha Z. Mubdi, Colin B. Begg, and Kevin C. Oeffinger, Memorial Sloan Kettering Cancer Center; Jyoti Malhotra, Mount Sinai Medical Center, New York, NY; Wendy M. Leisenring, Fred Hutchinson Cancer Research Center, Seattle, WA; Marilyn Stovall and Susan A. Smith, University of Texas MD Anderson Cancer Center, Houston, TX; Sue Hammond, Nationwide Children's Hospital, Columbus, OH; Tara O. Henderson, University of Chicago Medicine Comer Children's Hospital, Chicago, IL; John D. Boice, Vanderbilt-Ingram Cancer Center, Nashville; Melissa M. Hudson and Leslie L. Robison, St Jude Children's Research Hospital, Memphis, TN; Lisa R. Diller and Lisa B. Kenney, Dana-Farber Cancer Institute, Boston, MA; Smita Bhatia, City of Hope National Medical Center, Duarte, CA; and Joseph P. Neglia, University of Minnesota Masonic Cancer Center, Minneapolis, MN
| | - Joseph P Neglia
- Chaya S. Moskowitz, Joanne F. Chou, Suzanne L. Wolden, Jonine L. Bernstein, Danielle Novetsky Friedman, Nidha Z. Mubdi, Colin B. Begg, and Kevin C. Oeffinger, Memorial Sloan Kettering Cancer Center; Jyoti Malhotra, Mount Sinai Medical Center, New York, NY; Wendy M. Leisenring, Fred Hutchinson Cancer Research Center, Seattle, WA; Marilyn Stovall and Susan A. Smith, University of Texas MD Anderson Cancer Center, Houston, TX; Sue Hammond, Nationwide Children's Hospital, Columbus, OH; Tara O. Henderson, University of Chicago Medicine Comer Children's Hospital, Chicago, IL; John D. Boice, Vanderbilt-Ingram Cancer Center, Nashville; Melissa M. Hudson and Leslie L. Robison, St Jude Children's Research Hospital, Memphis, TN; Lisa R. Diller and Lisa B. Kenney, Dana-Farber Cancer Institute, Boston, MA; Smita Bhatia, City of Hope National Medical Center, Duarte, CA; and Joseph P. Neglia, University of Minnesota Masonic Cancer Center, Minneapolis, MN
| | - Colin B Begg
- Chaya S. Moskowitz, Joanne F. Chou, Suzanne L. Wolden, Jonine L. Bernstein, Danielle Novetsky Friedman, Nidha Z. Mubdi, Colin B. Begg, and Kevin C. Oeffinger, Memorial Sloan Kettering Cancer Center; Jyoti Malhotra, Mount Sinai Medical Center, New York, NY; Wendy M. Leisenring, Fred Hutchinson Cancer Research Center, Seattle, WA; Marilyn Stovall and Susan A. Smith, University of Texas MD Anderson Cancer Center, Houston, TX; Sue Hammond, Nationwide Children's Hospital, Columbus, OH; Tara O. Henderson, University of Chicago Medicine Comer Children's Hospital, Chicago, IL; John D. Boice, Vanderbilt-Ingram Cancer Center, Nashville; Melissa M. Hudson and Leslie L. Robison, St Jude Children's Research Hospital, Memphis, TN; Lisa R. Diller and Lisa B. Kenney, Dana-Farber Cancer Institute, Boston, MA; Smita Bhatia, City of Hope National Medical Center, Duarte, CA; and Joseph P. Neglia, University of Minnesota Masonic Cancer Center, Minneapolis, MN
| | - Leslie L Robison
- Chaya S. Moskowitz, Joanne F. Chou, Suzanne L. Wolden, Jonine L. Bernstein, Danielle Novetsky Friedman, Nidha Z. Mubdi, Colin B. Begg, and Kevin C. Oeffinger, Memorial Sloan Kettering Cancer Center; Jyoti Malhotra, Mount Sinai Medical Center, New York, NY; Wendy M. Leisenring, Fred Hutchinson Cancer Research Center, Seattle, WA; Marilyn Stovall and Susan A. Smith, University of Texas MD Anderson Cancer Center, Houston, TX; Sue Hammond, Nationwide Children's Hospital, Columbus, OH; Tara O. Henderson, University of Chicago Medicine Comer Children's Hospital, Chicago, IL; John D. Boice, Vanderbilt-Ingram Cancer Center, Nashville; Melissa M. Hudson and Leslie L. Robison, St Jude Children's Research Hospital, Memphis, TN; Lisa R. Diller and Lisa B. Kenney, Dana-Farber Cancer Institute, Boston, MA; Smita Bhatia, City of Hope National Medical Center, Duarte, CA; and Joseph P. Neglia, University of Minnesota Masonic Cancer Center, Minneapolis, MN
| | - Kevin C Oeffinger
- Chaya S. Moskowitz, Joanne F. Chou, Suzanne L. Wolden, Jonine L. Bernstein, Danielle Novetsky Friedman, Nidha Z. Mubdi, Colin B. Begg, and Kevin C. Oeffinger, Memorial Sloan Kettering Cancer Center; Jyoti Malhotra, Mount Sinai Medical Center, New York, NY; Wendy M. Leisenring, Fred Hutchinson Cancer Research Center, Seattle, WA; Marilyn Stovall and Susan A. Smith, University of Texas MD Anderson Cancer Center, Houston, TX; Sue Hammond, Nationwide Children's Hospital, Columbus, OH; Tara O. Henderson, University of Chicago Medicine Comer Children's Hospital, Chicago, IL; John D. Boice, Vanderbilt-Ingram Cancer Center, Nashville; Melissa M. Hudson and Leslie L. Robison, St Jude Children's Research Hospital, Memphis, TN; Lisa R. Diller and Lisa B. Kenney, Dana-Farber Cancer Institute, Boston, MA; Smita Bhatia, City of Hope National Medical Center, Duarte, CA; and Joseph P. Neglia, University of Minnesota Masonic Cancer Center, Minneapolis, MN
| |
Collapse
|
55
|
Tieu MT, Cigsar C, Ahmed S, Ng A, Diller L, Millar BA, Crystal P, Hodgson DC. Breast cancer detection among young survivors of pediatric Hodgkin lymphoma with screening magnetic resonance imaging. Cancer 2014; 120:2507-13. [PMID: 24888639 PMCID: PMC4283737 DOI: 10.1002/cncr.28747] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2013] [Revised: 02/05/2014] [Accepted: 02/05/2014] [Indexed: 02/05/2023]
Abstract
BACKGROUND Female survivors of pediatric Hodgkin lymphoma (HL) who have received chest radiotherapy are at increased risk of breast cancer. Guidelines for early breast cancer screening among these survivors are based on little data regarding clinical outcomes. This study reports outcomes of breast cancer screening with MRI and mammography (MMG) after childhood HL. METHODS We evaluated the results of breast MRI and MMG screening among 96 female survivors of childhood HL treated with chest radiotherapy. Outcomes measured included imaging sensitivity and specificity, breast cancer characteristics, and incidence of additional imaging and breast biopsy. RESULTS Median age at first screening was 30 years, and the median number of MRI screening rounds was 3. Ten breast cancers were detected in 9 women at a median age of 39 years (range, 24-43 years). Half were invasive and half were preinvasive. The median size of invasive tumors was 8 mm (range, 3-15 mm), and none had lymph node involvement. Sensitivity and specificity of the screening modalities were as follows: for MRI alone, 80% and 93.5%, respectively; MMG alone, 70% and 95%, respectively; both modalities combined, 100% and 88.6%, respectively. All invasive tumors were detected by MRI. Additional investigations were required in 52 patients, (54%), and 26 patients (27%) required breast biopsy, with 10 patients requiring more than 1 biopsy. CONCLUSIONS Screening including breast MRI with MMG has high sensitivity and specificity in pediatric HL survivors, with breast cancers detected at an early stage, although it is associated with a substantial rate of additional investigations. Cancer 2014;120:2507–2513. © 2014 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. Screening female survivors of pediatric Hodgkin Lymphoma for breast cancer with MRI and mammography detected tumors at an earlier stage than prior studies of mammography alone, although a substantial proportion of women required additional tests for benign imaging findings. The 5-year cumulative incidence of invasive or preinvasive tumors after initiating screening was 10.8%.
Collapse
Affiliation(s)
- Minh Thi Tieu
- Radiation Medicine Program, Princess Margaret Hospital, and the Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada
| | | | | | | | | | | | | | | |
Collapse
|
56
|
Armstrong GT, Kawashima T, Leisenring W, Stratton K, Stovall M, Hudson MM, Sklar CA, Robison LL, Oeffinger KC. Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. J Clin Oncol 2014; 32:1218-27. [PMID: 24638000 DOI: 10.1200/jco.2013.51.1055] [Citation(s) in RCA: 374] [Impact Index Per Article: 37.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE The first generation of childhood cancer survivors is now aging into their fourth and fifth decades of life, yet health risks across the aging spectrum are not well established. METHODS Analyses included 14,359 5-year survivors from the Childhood Cancer Survivor Study, who were first diagnosed when they were younger than 21 years old and who received follow-up for a median of 24.5 years after diagnosis (range, 5.0 to 39.3 years) along with 4,301 of their siblings. Among the survivors, 5,604 were at least 35 years old (range, 35 to 62 years) at last follow-up. Severe, disabling, life-threatening, and fatal health conditions more than 5 years from diagnosis were classified using the Common Terminology Criteria for Adverse Events, grades 3 to 5 (National Cancer Institute). RESULTS The cumulative incidence of a severe, disabling, life-threatening, or fatal health condition was greater among survivors than siblings (53.6%; 95% CI, 51.5 to 55.6; v 19.8%; 95% CI, 17.0 to 22.7) by age 50 years. When comparing survivors with siblings, hazard ratios (HR) were significantly increased within the age group of 5 to 19 years (HR, 6.8; 95% CI, 5.5 to 8.3), age group of 20 to 34 years (HR, 3.8; 95% CI, 3.2 to 4.5), and the ≥ 35 years group (HR, 5.0; 95% CI, 4.1 to 6.1), with the HR significantly higher among those ≥ 35 years versus those 20 to 34 years old (P = .03). Among survivors who reached age 35 years without a previous grade 3 or 4 condition, 25.9% experienced a subsequent grade 3 to 5 condition within 10 years, compared with 6.0% of siblings (P < .001). CONCLUSION Elevated risk for morbidity and mortality among survivors increases further beyond the fourth decade of life, which affects the future clinical demands of this population relative to ongoing surveillance and interventions.
Collapse
Affiliation(s)
- Gregory T Armstrong
- Gregory T. Armstrong, Melissa M. Hudson, Leslie L Robison, St Jude Children's Research Hospital, Memphis, TN; Toana Kawashima, Wendy Leisenring, Kayla Stratton, Fred Hutchinson Cancer Research Center, Seattle, WA; Marilyn Stovall, The University of Texas MD Anderson Cancer Center, Houston, TX; Charles A. Sklar, Kevin C. Oeffinger, Memorial Sloan-Kettering Cancer Center, New York, NY
| | | | | | | | | | | | | | | | | |
Collapse
|
57
|
Oeffinger KC, Baxi SS, Novetsky Friedman D, Moskowitz CS. Solid tumor second primary neoplasms: who is at risk, what can we do? Semin Oncol 2014; 40:676-89. [PMID: 24331190 DOI: 10.1053/j.seminoncol.2013.09.012] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Eighteen percent of incident malignancies in the United States are a second (or subsequent) cancer. Second primary neoplasms (SPNs), particularly solid tumors, are a major cause of mortality and serious morbidity among cancer survivors successfully cured of their first cancer. Multiple etiologies may lead to a cancer survivor subsequently being diagnosed with an SPN, including radiotherapy for the first cancer, unhealthy lifestyle behaviors, genetic factors, aging, or an interaction between any of these factors. In this article, we discuss these factors and synthesize this information for use in clinical practice, including preventive strategies and screening recommendations for SPNs.
Collapse
Affiliation(s)
- Kevin C Oeffinger
- Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY; Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY.
| | - Shrujal S Baxi
- Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
| | | | - Chaya S Moskowitz
- Department of Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY
| |
Collapse
|
58
|
Suh E, Daugherty CK, Wroblewski K, Lee H, Kigin ML, Rasinski KA, Ford JS, Tonorezos ES, Nathan PC, Oeffinger KC, Henderson TO. General internists' preferences and knowledge about the care of adult survivors of childhood cancer: a cross-sectional survey. Ann Intern Med 2014; 160:11-7. [PMID: 24573662 PMCID: PMC4337806 DOI: 10.7326/m13-1941] [Citation(s) in RCA: 129] [Impact Index Per Article: 12.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND Adult childhood cancer survivors (CCSs) are at high risk for illness and premature death. Little is known about the physicians who provide their routine medical care. OBJECTIVE To determine general internists' self-reported attitudes and knowledge about the care of CCSs. DESIGN Cross-sectional survey. SETTING Mailed survey delivered between September 2011 and August 2012. PARTICIPANTS Random sample of 2000 U.S. general internists. MEASUREMENTS Care preferences, comfort levels with caring for CCSs (7-point Likert scale: 1 = very uncomfortable, 7 = very comfortable), familiarity with available surveillance guidelines (7-point Likert scale: 1 = very unfamiliar, 7 = very familiar), and concordance with Children's Oncology Group Long-Term Follow-Up Guidelines in response to a clinical vignette. RESULTS The response rate was 61.6% (1110 of 1801). More than half the internists (51.1%) reported caring for at least 1 CCS; 72.0% of these internists never received a treatment summary. On average, internists were "somewhat uncomfortable" caring for survivors of Hodgkin lymphoma, acute lymphoblastic leukemia, and osteosarcoma. Internists reported being "somewhat unfamiliar" with available surveillance guidelines. In response to a clinical vignette about a young adult survivor of Hodgkin lymphoma, 90.6% of respondents did not appropriately recommend yearly breast cancer surveillance, 85.1% did not appropriately recommended cardiac surveillance, and 23.6% did not appropriately recommend yearly thyroid surveillance. Access to surveillance guidelines and treatment summaries were identified as the most useful resources for caring for CCSs. LIMITATION Findings, based on self-report, may not reflect actual clinical practice. CONCLUSION Although most general internists report involvement in the care of CCSs, many seem unfamiliar with available surveillance guidelines and would prefer to follow patients in collaboration with a cancer center. PRIMARY FUNDING SOURCE National Cancer Institute.
Collapse
|
59
|
Henderson TO, Ness KK, Cohen HJ. Accelerated aging among cancer survivors: from pediatrics to geriatrics. Am Soc Clin Oncol Educ Book 2014:e423-e430. [PMID: 24857133 DOI: 10.14694/edbook_am.2014.34.e423] [Citation(s) in RCA: 101] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
There are almost 14-million cancer survivors in the United States and the population is growing. Almost two-thirds of these survivors are age 65 or older. Given this, it is imperative to understand the impact of cancer and its therapies on the aging process. Childhood cancer survivors, diagnosed with cancer at age 21 or younger, particularly females, have rates of frailty similar to rates in older adults. This phenomenon appears to start early, suggesting an aging phenotype. Frailty among childhood cancer survivors increases risk for chronic disease and mortality. Adults diagnosed with cancer are faced with the effects of cancer and its therapies compounded by the issues of multiple morbidities that occur with the typical aging process. Intervention studies to date have focused on smoking cessation, diet, and exercise, as well as improving rates of late effects surveillance in childhood cancer survivors. No intervention studies have specifically addressed the issue of frailty or multiple morbidities in cancer survivors. Concerted efforts must continue to create and disseminate survivorship care plans to all cancer survivors.
Collapse
Affiliation(s)
- Tara O Henderson
- From the University of Chicago Comer Children's Hospital, Chicago, IL; St. Jude Children's Research Hospital, Memphis, TN; Duke University, Durham, NC
| | - Kirsten K Ness
- From the University of Chicago Comer Children's Hospital, Chicago, IL; St. Jude Children's Research Hospital, Memphis, TN; Duke University, Durham, NC
| | - Harvey Jay Cohen
- From the University of Chicago Comer Children's Hospital, Chicago, IL; St. Jude Children's Research Hospital, Memphis, TN; Duke University, Durham, NC
| |
Collapse
|
60
|
Vares G, Cui X, Wang B, Nakajima T, Nenoi M. Generation of breast cancer stem cells by steroid hormones in irradiated human mammary cell lines. PLoS One 2013; 8:e77124. [PMID: 24146960 PMCID: PMC3797732 DOI: 10.1371/journal.pone.0077124] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2012] [Accepted: 09/08/2013] [Indexed: 12/14/2022] Open
Abstract
Exposure to ionizing radiation was shown to result in an increased risk of breast cancer. There is strong evidence that steroid hormones influence radiosensitivity and breast cancer risk. Tumors may be initiated by a small subpopulation of cancer stem cells (CSCs). In order to assess whether the modulation of radiation-induced breast cancer risk by steroid hormones could involve CSCs, we measured by flow cytometry the proportion of CSCs in irradiated breast cancer cell lines after progesterone and estrogen treatment. Progesterone stimulated the expansion of the CSC compartment both in progesterone receptor (PR)-positive breast cancer cells and in PR-negative normal cells. In MCF10A normal epithelial PR-negative cells, progesterone-treatment and irradiation triggered cancer and stemness-associated microRNA regulations (such as the downregulation of miR-22 and miR-29c expression), which resulted in increased proportions of radiation-resistant tumor-initiating CSCs.
Collapse
Affiliation(s)
- Guillaume Vares
- Research Center for Radiation Protection, National Institute of Radiological Sciences, Chiba, Japan
- * E-mail:
| | - Xing Cui
- Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan
| | - Bing Wang
- Research Center for Radiation Protection, National Institute of Radiological Sciences, Chiba, Japan
| | - Tetsuo Nakajima
- Research Center for Radiation Protection, National Institute of Radiological Sciences, Chiba, Japan
| | - Mitsuru Nenoi
- Research Center for Radiation Protection, National Institute of Radiological Sciences, Chiba, Japan
| |
Collapse
|
61
|
Nelson AL. Controversies Regarding Mammography, Breast Self-Examination, and Clinical Breast Examination. Obstet Gynecol Clin North Am 2013; 40:413-27. [DOI: 10.1016/j.ogc.2013.05.001] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
62
|
Corkum M, Hayden JA, Kephart G, Urquhart R, Schlievert C, Porter G. Screening for new primary cancers in cancer survivors compared to non-cancer controls: a systematic review and meta-analysis. J Cancer Surviv 2013; 7:455-63. [PMID: 23645522 PMCID: PMC3734601 DOI: 10.1007/s11764-013-0278-6] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2013] [Accepted: 03/04/2013] [Indexed: 01/21/2023]
Abstract
PURPOSE The goal of this study was to synthesize evidence comparing cancer screening receipt between cancer survivors and non-cancer controls by conducting a systematic review and meta-analysis. METHODS We searched PubMed, EMBASE, and CINAHL databases from inception through April 1, 2010 using search terms related to cancer, survivorship, and cancer screening. Studies were included if they reported a comparison of cancer screening receipt between cancer survivors and non-cancer controls. We performed a meta-analysis on the effect of cancer survivorship on breast, cervical, colorectal, and prostate cancer screening receipt. RESULTS Our search strategy identified 1,778 titles, of which 20 met our inclusion/exclusion criteria. In our meta-analyses, cancer survivors were more likely to be screened for breast, cervical, colorectal, and prostate cancer than non-cancer controls (pooled odds ratio, 1.27; 95 % CI, 1.19-1.36). We observed significant heterogeneity between studies, most of which remained unexplained after subgroup and sensitivity analyses. Important contextual factors, such as how screening programs operate, were not reported in the primary literature. Many cancer survivors (along with non-cancer controls) still did not receive cancer screening. CONCLUSION Compared with non-cancer controls, cancer survivors receive more frequent screening for new primary breast, cervical, colorectal, and prostate cancers. Future research should seek to determine whether increased uptake of cancer screening is associated with improved outcomes during cancer survivorship. IMPLICATIONS FOR CANCER SURVIVORS Our systematic review and meta-analysis demonstrated that cancer survivors received more frequent screening for second primary breast, cervical, colorectal, and prostate cancers than non-cancer controls. As many cancer survivors are at an increased risk of developing a second primary cancer, future research should seek to determine whether this increased uptake of cancer screening in cancer survivors leads to improved outcomes during cancer survivorship.
Collapse
Affiliation(s)
- Mark Corkum
- Department of Community Health and Epidemiology, Dalhousie University, 5790 University Ave, Halifax, NS Canada
| | - Jill A. Hayden
- Department of Community Health and Epidemiology, Dalhousie University, 5790 University Ave, Halifax, NS Canada
| | - George Kephart
- Department of Community Health and Epidemiology, Dalhousie University, 5790 University Ave, Halifax, NS Canada
| | - Robin Urquhart
- Cancer Outcomes Research Program, Cancer Care Nova Scotia, Halifax, NS Canada
| | - Coralynne Schlievert
- Department of Community Health and Epidemiology, Dalhousie University, 5790 University Ave, Halifax, NS Canada
| | - Geoffrey Porter
- Department of Community Health and Epidemiology, Dalhousie University, 5790 University Ave, Halifax, NS Canada
- Cancer Outcomes Research Program, Cancer Care Nova Scotia, Halifax, NS Canada
- Department of Surgery, Dalhousie University, Halifax, NS Canada
| |
Collapse
|
63
|
Sung JS, Dershaw DD. Breast Magnetic Resonance Imaging for Screening High-Risk Women. Magn Reson Imaging Clin N Am 2013; 21:509-17. [DOI: 10.1016/j.mric.2013.02.006] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
64
|
Boucher AA, Blaes AH. Prophylactic mastectomy: a treatment alternative for Hodgkin survivors? Clin Breast Cancer 2013; 13:307-8. [PMID: 23891588 DOI: 10.1016/j.clbc.2013.06.001] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2013] [Accepted: 06/11/2013] [Indexed: 01/26/2023]
Affiliation(s)
- Alexander A Boucher
- Department of Internal Medicine and Pediatrics, University of Minnesota, Minneapolis, MN.
| | | |
Collapse
|
65
|
Deyell RJ, Lorenzi M, Ma S, Rassekh SR, Collet JP, Spinelli JJ, McBride ML. Antidepressant use among survivors of childhood, adolescent and young adult cancer: a report of the Childhood, Adolescent and Young Adult Cancer Survivor (CAYACS) Research Program. Pediatr Blood Cancer 2013; 60:816-22. [PMID: 23281214 DOI: 10.1002/pbc.24446] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/11/2012] [Accepted: 11/26/2012] [Indexed: 11/12/2022]
Abstract
BACKGROUND Although survivors of childhood, adolescent, and young adult (AYA) cancer are at risk for late psychological sequelae, it is unclear if they are more likely to be prescription antidepressant users than their peers. PROCEDURE All 5-year survivors of childhood or AYA cancer diagnosed before age 25 years in British Columbia from 1970 to 1995 were identified. Those with complete follow-up in the provincial health insurance registry from 2001 to 2004 were included (n = 2,389). A birth-cohort and gender-matched set of population controls 10 times the size of the survivor group was randomly selected (n = 23,890). All prescriptions filled between 2001 and 2004 were identified through linkage to the provincial prescription drug administrative database. Logistic regression analyses determined the impact of cancer survivorship on the likelihood of ever filling an antidepressant prescription. RESULTS After adjusting for sociodemographic factors, survivors of childhood and AYA cancer were more likely to have filled an antidepressant prescription compared to controls (OR 1.21, 95% CI 1.09-1.35). Cancer survivors had an increased likelihood of using all categories of antidepressants, and of using drugs from two or more antidepressant categories, compared to peers (OR 1.31, 95% CI 1.11-1.55 [≥2 antidepressant categories]). Treatment was not a significant predictor of antidepressant use. Female survivors, those in young adulthood and those more than 20 years post-treatment had increased antidepressant use. CONCLUSIONS Survivors of childhood and AYA cancer are more likely to fill antidepressant prescriptions compared to peer controls. This may indirectly reflect an increased underlying prevalence of mental health conditions among survivors.
Collapse
Affiliation(s)
- Rebecca J Deyell
- Division of Oncology, Hematology and Bone Marrow Transplant, British Columbia Children's Hospital and University of British Columbia, Vancouver, British Columbia, Canada
| | | | | | | | | | | | | |
Collapse
|
66
|
Jacobs LA, Pucci DA. Adult Survivors of Childhood Cancer: The Medical and Psychosocial Late Effects of Cancer Treatment and the Impact on Sexual and Reproductive Health. J Sex Med 2013; 10 Suppl 1:120-6. [DOI: 10.1111/jsm.12050] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
|
67
|
Colin C, de Vathaire F, Noël A, Charlot M, Devic C, Foray N, Valette PJ. Updated Relevance of Mammographic Screening Modalities in Women Previously Treated with Chest Irradiation for Hodgkin Disease. Radiology 2012; 265:669-76. [DOI: 10.1148/radiol.12120794] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
68
|
Schwartz LA, Kazak AE, Derosa BW, Hocking MC, Hobbie WL, Ginsberg JP. The role of beliefs in the relationship between health problems and posttraumatic stress in adolescent and young adult cancer survivors. J Clin Psychol Med Settings 2012; 19:138-46. [PMID: 21964825 DOI: 10.1007/s10880-011-9264-1] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
In addition to the potential for ongoing health concerns, adolescent and young adult (AYA) childhood cancer survivors frequently report posttraumatic stress symptoms (PTSS). The current study examines whether beliefs about health moderate the relationship between the number of health problems and PTSS 2 months later in 140 survivors. Beliefs, as measured by scales of the Health Competence Beliefs Inventory (HCBI), negatively related to PTSS while health problems positively related to PTSS. Three scales of the HCBI-health perceptions, satisfaction with healthcare and cognitive competence--were significant moderators. The relationship between health problems and PTSS was stronger in the presence of less adaptive beliefs. These beliefs represent potentially malleable intervention targets for reducing PTSS in childhood cancer survivors.
Collapse
Affiliation(s)
- Lisa A Schwartz
- The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
| | | | | | | | | | | |
Collapse
|
69
|
Risk of Late Mortality and Second Malignant Neoplasms among 5-Year Survivors of Young Adult Cancer: A Report of the Childhood, Adolescent, and Young Adult Cancer Survivors Research Program. J Cancer Epidemiol 2012; 2012:103032. [PMID: 23008713 PMCID: PMC3447326 DOI: 10.1155/2012/103032] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2012] [Revised: 07/23/2012] [Accepted: 08/08/2012] [Indexed: 11/17/2022] Open
Abstract
We conducted a population-based retrospective study to assess the long-term risks of overall and cause-specific mortality and second malignant neoplasm (SMN) among survivors of young adult cancer compared to the risk in British Columbia (BC) population and to evaluate the effects of demographic and clinical factors on risk. 1248 5-year survivors of young adult cancer diagnosed 1970–1995 between 20 and 24 years of age were identified from the BC Cancer Registry and followed to the end of 2007. Standardized mortality ratios (SMRs) and standardized incidence ratios (SIRs) were calculated. The Cox proportional hazards model was used to estimate the effects of different demographic and disease-related characteristics on the risk of death and SMN. A total of 138 deaths and 62 SMNs were observed during follow-up. The overall SMR was 5.9 (95% CI 4.9–6.9) and the absolute excess risk was 5.3 per 1,000 person-years. The overall SIR was 3.0 (95% CI 2.3–3.8). Treatment with radiation resulted in increased risks of death and SMN. These observed increased risks emphasize the importance of prevention, surveillance, and treatment of late effects in survivors of young adult cancers.
Collapse
|
70
|
Cox CL, Zhu L, Hudson MM, Steen BD, Robison LL, Oeffinger KC. Survivor typologies predict medical surveillance participation: the childhood cancer survivor study. Psychooncology 2012; 22:1534-42. [PMID: 22968964 DOI: 10.1002/pon.3167] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2012] [Revised: 08/01/2012] [Accepted: 08/03/2012] [Indexed: 01/28/2023]
Abstract
BACKGROUND Adult survivors of childhood cancer adhere poorly to recommended medical surveillance. We sought to identify modifiable factors that contribute to non-adherence. METHODS Latent class analysis categorized survivors (ages 18-52 years) at risk of cardiac, breast, or bone late sequelae on the basis of their health-related concerns, fears, and motivation. These classifications were compared at two time points for self-reported adherence to recommended echocardiography, mammography, and bone densitometry screening. RESULTS Three classes (worried, collaborative, and self-controlling) characterized survivors in each of the three risk groups: cardiac (N=564; Bayesian information criterion [BIC] =10,824.66; Lo-Mendell-Rubin parametric likelihood ratio test [LRMLRT] P= .002), breast (N=584; BIC=11,779.97; LRMLRT P< .001), and bone (N=613; BIC=11,773.56; LMRLRT P= .028). Only 9% of at-risk survivors in the self-controlling class reported undergoing bone density screening in 2005, compared with 17.2% in the collaborative class (P= .034). Thirteen percent of the self-controlling, 24% of collaborative (P= .025), and 34% of worried (P= .010) classes reported undergoing bone densitometry in 2009. Whereas 73% of at-risk survivors in the worried class reported having had an echocardiogram in 2009, only 57% of the collaborative (P= .040) and 43% of self-controlling (P< .001) classes did. In 2005 and 2009, respectively, fewer survivors in the self-controlling class (37% and 53%) than in the collaborative (51%, P= .038 and 70%, P= .01) and worried (58%, P= .002 and 69%, P= .025) classes reported undergoing mammograms. CONCLUSIONS Modifiable intrapersonal characteristics associated with these three classes predict self-reported participation in medical surveillance. Continued observation and validation of these survivor profiles may inform tailored interventions to enhance survivors' screening participation. Copyright © 2012 John Wiley & Sons, Ltd.
Collapse
Affiliation(s)
- Cheryl L Cox
- Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN 38105-2794, USA.
| | | | | | | | | | | |
Collapse
|
71
|
Breast cancer surveillance in patients treated by radiotherapy for Hodgkin's lymphoma. LA RADIOLOGIA MEDICA 2012; 118:401-14. [PMID: 22872454 DOI: 10.1007/s11547-012-0862-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/17/2011] [Accepted: 09/26/2011] [Indexed: 10/28/2022]
Abstract
PURPOSE The authors evaluated the relative risk of developing radiation-induced breast cancer (BC) in women treated with radiotherapy for Hodgkin's disease (HD) and analysed the imaging features of these breast neoplasms. MATERIALS AND METHODS We retrospectively studied 54 women who had all undergone radiotherapy between 1980 and 2010 (median age, 36.6 years). Women aged ≤30 years were screened with clinical breast examination, ultrasound (US) and, if necessary, mammography; women >30 years had clinical breast examination, US and mammography. Three women underwent magnetic resonance (MR) imaging as well. RESULTS Mammography detected seven invasive breast cancers in 6/54 women (11.1%). Median age at diagnosis was 26.1 years for HD and 42.4 for breast cancer. Breast cancer was diagnosed following a median latent period from radiotherapy of 15.1 years. Mean radiation dose was 37.6 Gy in women who developed breast cancer and 31.3 Gy in the other women. CONCLUSIONS In our study, women who were exposed to radiation for HD had a 6.2-fold higher risk of developing breast cancer than the general population. In consideration of the young age and high breast density, women aged ≤30 years should be monitored by US and MR imaging; women aged >30 years should be monitored by US, mammography and, when necessary, MR imaging.
Collapse
|
72
|
Haberer S, Belin L, Le Scodan R, Kirova YM, Savignoni A, Stevens D, Moisson P, Decaudin D, Pierga JY, Reyal F, Campana F, Fourquet A, Bollet MA. [Breast conserving surgery in locoregional treatment of breast carcinoma after Hodgkin lymphoma]. Cancer Radiother 2012; 16:128-35. [PMID: 22341508 DOI: 10.1016/j.canrad.2011.10.013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2011] [Revised: 09/09/2011] [Accepted: 10/12/2011] [Indexed: 11/27/2022]
Abstract
PURPOSE To report characteristics and outcome of breast cancer after irradiation for Hodgkin lymphoma with special focus on breast conservation surgery. PATIENTS AND METHODS Medical records of 72 women who developed either ductal carcinoma in situ or stage I-III invasive carcinoma of the breast after Hodgkin lymphoma between 1978 and 2009 were retrospectively reviewed. RESULTS Median age at Hodgkin lymphoma diagnosis was 23 years old. Median total dose received by the mediastinum was 40 Gy, mostly by a mantle field technique. Breast cancer occurred after a median time interval of 21 years. Ductal invasive carcinoma and ductal carcinoma in situ represented respectively 71% and 19% of the cases. Locoregional treatment for breast cancer consisted of mastectomy with or without radiotherapy in 39 patients and of lumpectomy with or without adjuvant radiotherapy in 32 patients. The isocentric lateral decubitus radiation technique was used in 17 patients after breast conserving surgery (57%). With a median follow-up of 7 years, 5-year overall survival rate and locoregional control rate were respectively 74.5% and 82% for invasive carcinoma and 100% and 92% for in situ carcinoma. Thirteen patients died of progressive breast cancer and contralateral breast cancer was diagnosed in ten patients (14%). CONCLUSIONS Breast conserving treatment can be an option for breast cancers that occur after Hodgkin lymphoma despite prior thoracic irradiation. It should consist of lumpectomy and adjuvant breast radiotherapy with use of adequate techniques, such as the lateral decubitus isocentric position.
Collapse
Affiliation(s)
- S Haberer
- Département de radiothérapie, institut Curie, Paris, France.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
73
|
Oeffinger KC, Tonorezos ES. The cancer is over, now what?: Understanding risk, changing outcomes. Cancer 2011; 117:2250-7. [PMID: 21523742 DOI: 10.1002/cncr.26051] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
About 26,000 adolescents and young adults ages 15 to 29 years are diagnosed with invasive cancer each year. Although >80% will survive beyond 5 years from their cancer diagnosis, many will develop serious morbidity or die prematurely secondary to health problems in part related to their cancer therapy. This article provides a brief overview of mortality, morbidity, and health status among long-term survivors of adolescent and young adult (AYA) cancer. Four examples were used to illustrate the potential of risk-reducing strategies: breast cancer after chest irradiation, coronary artery disease after chest irradiation, cardiovascular disease in testicular cancer survivors, and the multitude of health problems faced by survivors receiving an allogeneic hematopoietic stem cell transplant. A conceptual model for risk-based health care was presented and future directions of the delivery of care for AYA cancer survivors discussed.
Collapse
Affiliation(s)
- Kevin C Oeffinger
- Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York 10064, USA.
| | | |
Collapse
|
74
|
Haberer S, Belin L, Le Scodan R, Kirova YM, Savignoni A, Stevens D, Moisson P, Decaudin D, Pierga JY, Reyal F, Campana F, Fourquet A, Bollet MA. Locoregional treatment for breast carcinoma after Hodgkin's lymphoma: the breast conservation option. Int J Radiat Oncol Biol Phys 2011; 82:e145-52. [PMID: 21605948 DOI: 10.1016/j.ijrobp.2011.03.013] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2010] [Revised: 03/01/2011] [Accepted: 03/17/2011] [Indexed: 01/30/2023]
Abstract
PURPOSE To report clinical and pathologic characteristics and outcome of breast cancer (BC) after irradiation for Hodgkin's lymphoma (HL) in women treated at the Institut Curie, with a special focus on the breast-conserving option. METHODS AND MATERIALS Medical records of 72 women who developed either ductal carcinoma in situ or Stage I-III invasive carcinoma of the breast after HL between 1978 and 2009 were retrospectively reviewed. RESULTS Median age at HL diagnosis was 23 years (range, 14-53 years). Median total dose received by the mediastinum was 40 Gy, mostly by a mantle-field technique. Breast cancers occurred after a median interval of 21 years (range, 5-40 years). Ductal invasive carcinoma and ductal carcinoma in situ represented, respectively, 51 cases (71%) and 14 cases (19%). Invasive BCs consisted of 47 cT0-2 tumors (82%), 5 cN1-3 tumors (9%), and 20 Grade 3 tumors (35%). Locoregional treatment for BCs consisted of mastectomy with (3) or without (36) radiotherapy in 39 patients and lumpectomy with (30) or without (2) adjuvant radiotherapy in 32 patients. The isocentric lateral decubitus radiation technique was used in 17 patients after breast-conserving surgery (57%). With a median follow-up of 7 years, 5-year overall survival rate and locoregional control rate were, respectively, 74.5% (95% confidence interval [CI], 64-88%) and 82% (95% CI, 72-93%) for invasive carcinoma and 100% (95% CI, 100 -100%) and 92% (95% CI, 79-100%) for in situ carcinoma. In patients with invasive tumors, the 5-year distant disease-free survival rate was 79% (95% CI, 69-91%), and 13 patients died of progressive BC. Contralateral BC was diagnosed in 10 patients (14%). CONCLUSIONS Breast-conserving treatment can be an option for BCs that occur after HL, despite prior thoracic irradiation. It should consist of lumpectomy and adjuvant breast radiotherapy with use of adequate techniques, such as the lateral decubitus isocentric position, to protect the underlying heart and lung.
Collapse
Affiliation(s)
- Sophie Haberer
- Department of Radiation Oncology, Institut Curie, Paris, France.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
75
|
Oeffinger KC, Hudson MM, Mertens AC, Smith SM, Mitby PA, Eshelman-Kent DA, Ford JS, Jones JK, Kamani S, Robison LL. Increasing rates of breast cancer and cardiac surveillance among high-risk survivors of childhood Hodgkin lymphoma following a mailed, one-page survivorship care plan. Pediatr Blood Cancer 2011; 56:818-24. [PMID: 21370417 PMCID: PMC3749088 DOI: 10.1002/pbc.22696] [Citation(s) in RCA: 84] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/24/2010] [Accepted: 05/18/2010] [Indexed: 11/08/2022]
Abstract
BACKGROUND Hodgkin lymphoma (HL) survivors face substantially elevated risks of breast cancer and cardiovascular disease. They and their physicians are often unaware of these risks and surveillance recommendations. PROCEDURE A prospective one-arm study was conducted among a random sample of 72 HL survivors, ages 27-55 years, participating in the Childhood Cancer Survivor Study (CCSS) who were at increased risk for breast cancer and/or cardiomyopathy and had not had a screening mammogram or echocardiogram, respectively, within the prior 2 years. A one-page survivorship care plan with recommendations for surveillance was mailed to participants. In addition, survivors' primary physicians were contacted and provided patient-specific information and a web-based Virtual Information Center was made available for both survivors and physicians. Outcomes were assessed by telephone 6 months after the intervention. RESULTS The survivor participation (62/72; 86%) and 6-month retention (56/61; 92%) rates were high. Tension and anxiety, measured by the Profile of Mood States, did not increase following risk notification; 91% of survivors described their reactions to receiving the information in positive terms. At 6 months, 41% of survivors reported having completed the recommended mammogram; 20% reported having an echocardiogram (females 30%, males 10%). Only 29% of survivors visited the website. Nine physicians enrolled, and none used the study resources. CONCLUSION A mailed, personalized survivorship care plan was effective in communicating risk and increasing compliance with recommended medical surveillance. Internet- and telephone-based strategies to communicate risk were not utilized by survivors or physicians.
Collapse
Affiliation(s)
- Kevin C. Oeffinger
- Memorial Sloan-Kettering Cancer Center, Departments of Pediatrics and Medicine; 1275 York Ave, New York, NY 10065
| | - Melissa M. Hudson
- St. Jude Children’s Research Hospital, Department of Oncology; 262 Danny Thomas Place, Memphis, TN 38105
| | - Ann C. Mertens
- Emory University, Department of Pediatrics; 201 Dowman Drive, Atlanta, GA 30322
| | - Stephanie M. Smith
- Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305
| | - Pauline A. Mitby
- Children’s Hospitals and Clinics of Minnesota, Department of Hematology/Oncology; 2525 Chicago Ave. S., Minneapolis, MN 55404
| | - Debra A. Eshelman-Kent
- Cincinnati Children’s Hospital Medical Center, ATP Five Plus Long Term Cancer Survivor Clinic; 3333 Burnet Avenue, Cincinnati, OH 45229
| | - Jennifer S. Ford
- Memorial Sloan-Kettering Cancer Center, Departments of Pediatrics and Medicine; 1275 York Ave, New York, NY 10065
| | - Judith K. Jones
- The Degge Group, Ltd, 1616 North Fort Myer Drive, Suite 1430, Arlington, Virginia 22209
| | - Sharmila Kamani
- The Degge Group, Ltd, 1616 North Fort Myer Drive, Suite 1430, Arlington, Virginia 22209
| | - Leslie L. Robison
- St. Jude Children’s Research Hospital, Department of Oncology; 262 Danny Thomas Place, Memphis, TN 38105
| |
Collapse
|
76
|
Sung JS, Lee CH, Morris EA, Oeffinger KC, Dershaw DD. Screening Breast MR Imaging in Women with a History of Chest Irradiation. Radiology 2011; 259:65-71. [DOI: 10.1148/radiol.10100991] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
77
|
Armenian SH, Sun CL, Francisco L, Baker KS, Weisdorf DJ, Forman SJ, Bhatia S. Health behaviors and cancer screening practices in long-term survivors of hematopoietic cell transplantation (HCT): a report from the BMT Survivor Study. Bone Marrow Transplant 2011; 47:283-90. [PMID: 21423125 PMCID: PMC3134636 DOI: 10.1038/bmt.2011.60] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Patients undergoing HCT are at increased risk of chronic health conditions, including second malignant neoplasms and cardiovascular disease. Little is known about health behaviors and cancer screening practices among HCT survivors that could moderate the risk of these conditions. The BMTSS examined health behaviors and cancer screening practices in individuals who underwent HCT between 1976 and 1998, and survived 2+ years. Health behavior was deemed high-risk if an individual was a current smoker and if they reported risky alcohol intake (≥4 drinks/day [males], ≥ 3 drinks/day [females]) on days of alcohol consumption. Cancer screening assessment was per American Cancer Society recommendations. There were 1040 survivors: 42.7% underwent allogeneic HCT; 43.8% were female; median time from HCT: 7.4 years (range 2.0–27.7 years). Median age at study participation: 43.8 years (range 18.3–73.0 years). Multivariate regression analysis revealed younger age (<35 years) at study participation (Odds Ratio [OR]=4.7; p<0.01) and lower education (<college: OR=2.1; p<0.01) to be significantly associated with high-risk behavior. Survivors were significantly less likely to report high-risk behavior (OR=0.5; p<0.01), and more likely to have had a screening mammogram (OR=2.8; p=0.05) when compared to gender-matched sibling controls (N=309).
Collapse
Affiliation(s)
- S H Armenian
- Department of Population Sciences, City of Hope, Duarte, CA 91010-3000, USA
| | | | | | | | | | | | | |
Collapse
|
78
|
Doshi K, Kazak AE, Derosa BW, Schwartz LA, Hobbie W, Ginsberg J, Ittenbach RF. Measuring health-related beliefs of mothers of adolescent and young adult childhood cancer survivors. FAMILIES, SYSTEMS & HEALTH : THE JOURNAL OF COLLABORATIVE FAMILY HEALTHCARE 2011; 29:55-63. [PMID: 21417524 PMCID: PMC3143683 DOI: 10.1037/a0022198] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Childhood cancer has long-term implications for survivors and their family members. While the impact of cancer on the family continues into adulthood, little research exists on family related issues during this important developmental period. In order to advance our understanding of families of adolescent and young adult (AYA) childhood cancer survivors, a measure of health-related beliefs for parents of AYA cancer survivors was developed. Exploratory factor analysis based on the mothers' data was used to identify four factors among 23 items: Social Competence, Satisfaction with Healthcare, Health Perceptions, and Health Apprehension. The scales are associated with psychological distress, quality of life, and posttraumatic stress symptoms but unrelated to age of the child at diagnosis and cancer treatment intensity. The beliefs identified in this study are consistent with clinical observations of families of young adult survivors and provide indications for the importance of ongoing attention to the families of childhood cancer survivors.
Collapse
Affiliation(s)
- Kinjal Doshi
- Department of Psychology, University of Pennsylvania, Philadelphia, PA, USA
| | | | | | | | | | | | | |
Collapse
|
79
|
Castellino SM, Geiger AM, Mertens AC, Leisenring WM, Tooze JA, Goodman P, Stovall M, Robison LL, Hudson MM. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood 2011; 117:1806-16. [PMID: 21037086 PMCID: PMC3056636 DOI: 10.1182/blood-2010-04-278796] [Citation(s) in RCA: 261] [Impact Index Per Article: 20.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2010] [Accepted: 10/18/2010] [Indexed: 02/07/2023] Open
Abstract
The contribution of specific cancer therapies, comorbid medical conditions, and host factors to mortality risk after pediatric Hodgkin lymphoma (HL) is unclear. We assessed leading morbidities, overall and cause-specific mortality, and mortality risks among 2742 survivors of HL in the Childhood Cancer Survivor Study, a multi-institutional retrospective cohort study of survivors diagnosed from 1970 to 1986. Excess absolute risk for leading causes of death and cumulative incidence and standardized incidence ratios of key medical morbidities were calculated. Cox regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) of risks for overall and cause-specific mortality. Substantial excess absolute risk of mortality per 10,000 person-years was identified: overall 95.5; death due to HL 38.3, second malignant neoplasms 23.9, and cardiovascular disease 13.1. Risks for overall mortality included radiation dose ≥ 3000 rad ( ≥ 30 Gy; supra-diaphragm: HR, 3.8; 95% CI, 1.1-12.6; infradiaphragm + supradiaphragm: HR, 7.8; 95% CI, 2.4-25.1), exposure to anthracycline (HR, 2.6; 95% CI, 1.6-4.3) or alkylating agents (HR, 1.7; 95% CI, 1.2-2.5), non-breast second malignant neoplasm (HR, 2.6; 95% CI 1.4-5.1), or a serious cardiovascular condition (HR, 4.4; 95% CI 2.7-7.3). Excess mortality from second neoplasms and cardiovascular disease vary by sex and persist > 20 years of follow-up in childhood HL survivors.
Collapse
Affiliation(s)
- Sharon M Castellino
- Department of Pediatrics, Wake Forest University Health Sciences, Winston-Salem, NC 27157, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
80
|
Abstract
More than 25,000 allogeneic hematopoietic stem cell transplantations (allo-HCTs) are expected to be performed worldwide in 2010, a number that has been increasing yearly. With broadening indications, more options for allo-HCT, and improvement in survival, by 2020 there may be up to half a million long-term survivors after allo-HCT worldwide. These patients have increased risks for various late complications, which can cause morbidity and mortality. Most long-term survivors return to the care of their local hematologists/oncologists or primary care physicians, who may not be familiar with specialized monitoring recommendations for this patient population. The purpose of this article is to describe practical approaches to screening for and managing these late effects, with the goal of reducing preventable morbidity and mortality associated with allo-HCT.
Collapse
|
81
|
Nathan PC, Ness KK, Mahoney MC, Li Z, Hudson MM, Ford JS, Landier W, Stovall M, Armstrong GT, Henderson TO, Robison LL, Oeffinger KC. Screening and surveillance for second malignant neoplasms in adult survivors of childhood cancer: a report from the childhood cancer survivor study. Ann Intern Med 2010; 153:442-51. [PMID: 20921543 PMCID: PMC3084018 DOI: 10.7326/0003-4819-153-7-201010050-00007] [Citation(s) in RCA: 85] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
BACKGROUND Survivors of childhood cancer may develop a second malignant neoplasm during adulthood and therefore require regular surveillance. OBJECTIVE To examine adherence to population cancer screening guidelines by survivors at average risk for a second malignant neoplasm and adherence to cancer surveillance guidelines by survivors at high risk for a second malignant neoplasm. DESIGN Retrospective cohort study. SETTING The Childhood Cancer Survivor Study (CCSS), a 26-center study of long-term survivors of childhood cancer that was diagnosed between 1970 and 1986. PATIENTS 4329 male and 4018 female survivors of childhood cancer who completed a CCSS questionnaire assessing screening and surveillance for new cases of cancer. MEASUREMENTS Patient-reported receipt and timing of mammography, Papanicolaou smear, colonoscopy, or skin examination was categorized as adherent to the U.S. Preventive Services Task Force guidelines for survivors at average risk for breast or cervical cancer or the Children's Oncology Group guidelines for survivors at high risk for breast, colorectal, or skin cancer as a result of cancer therapy. RESULTS In average-risk female survivors, 2743 of 3392 (80.9%) reported having a Papanicolaou smear within the recommended period, and 140 of 209 (67.0%) reported mammography within the recommended period. In high-risk survivors, rates of recommended mammography among women were only 241 of 522 (46.2%) and the rates of colonoscopy and complete skin examinations among both sexes were 91 of 794 (11.5%) and 1290 of 4850 (26.6%), respectively. LIMITATIONS Data were self-reported. Participants in the CCSS are a selected group of survivors, and their adherence may not be representative of all survivors of childhood cancer. CONCLUSION Female survivors at average risk for a second malignant neoplasm show reasonable rates of screening for cervical and breast cancer. However, surveillance for new cases of cancer is very low in survivors at the highest risk for colon, breast, or skin cancer, suggesting that survivors and their physicians need education about their risks and recommended surveillance. PRIMARY FUNDING SOURCE The National Cancer Institute, National Institutes of Health, and the American Lebanese Syrian Associated Charities.
Collapse
|
82
|
Maeda N, Horibe K, Kato K, Kojima S, Tsurusawa M. Survey of childhood cancer survivors who stopped follow-up physician visits. Pediatr Int 2010; 52:806-12. [PMID: 20456086 DOI: 10.1111/j.1442-200x.2010.03158.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
BACKGROUND Childhood cancer cure rates have increased remarkably; however, survivors face an increased risk of morbidity and mortality. Survivors may benefit from anticipatory guidance and periodic surveillance to minimize morbidity and mortality. METHODS Subjects included 114 5-year survivors of childhood cancer who were diagnosed and treated in three hospitals in Nagoya between 1975 and 2001 and who stopped follow-up physician visits during the preceding 2 years. We conducted a survey of their socioeconomic status, knowledge about their diagnosis and late effects of treatment received, and current hospital attendance patterns. RESULTS Eighty-eight of 114 subjects replied. Sixty-six survivors knew about their disease, but only 26 knew about possible late effects of cancer treatment. Although 78 respondents indicated they were healthy and had no trouble in their daily lives, 46 had at least one chronic condition. In response to the question regarding why they did not visit the hospital regularly, many subjects responded that the physician-in-charge told them they did not need to visit the hospital anymore; others thought it was unnecessary to consult a physician because they were in good health. CONCLUSIONS Some cancer survivors who stop follow-up physician visits may still be suffering from cancer-related illnesses. Both survivor-related and physician-related barriers contribute to cancer survivors stopping follow-up physician visits. To ensure that survivors undergo appropriate follow-up visits, it is necessary to educate survivors, their families, and medical staff about the late effects of cancer and its treatment and the importance of long-term follow up.
Collapse
Affiliation(s)
- Naoko Maeda
- Department of Pediatrics, National Hospital Organization Nagoya Medical Center, Naka-ku, Nagoya, Japan.
| | | | | | | | | |
Collapse
|
83
|
Risk of breast cancer according to clinicopathologic features among long-term survivors of Hodgkin's lymphoma treated with radiotherapy. Br J Cancer 2010; 103:1081-4. [PMID: 20842115 PMCID: PMC2965878 DOI: 10.1038/sj.bjc.6605877] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
Abstract
Background: It is unknown whether breast cancer (BC) characteristics among young women treated with radiotherapy (RT) for Hodgkin's lymphoma (HL) differ from sporadic BC. Methods: Using population-based data, we calculated BC risk following HL according to clinicopathologic features. Results: Compared with BC in the general population, risks of oestrogen receptor (ER)-positive/progesterone receptor (PR)-positive and ER-negative/PR-negative BC in young, irradiated HL survivors were increased five-fold (95% confidence interval (CI)=3.81–6.35) and nine-fold (95% CI=6.93–12.25), respectively. Among 15-year survivors, relative risk of ER-negative/PR-negative BC exceeded by two-fold (P=0.002) than that of ER-positive/PR-positive BC. Conclusion: Radiotherapy may disproportionately contribute to the development of BC with adverse prognostic features among young HL survivors.
Collapse
|
84
|
Dowling E, Yabroff KR, Mariotto A, McNeel T, Zeruto C, Buckman D. Burden of illness in adult survivors of childhood cancers: findings from a population-based national sample. Cancer 2010; 116:3712-21. [PMID: 20564096 DOI: 10.1002/cncr.25141] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
BACKGROUND The number of adult survivors of childhood cancer in the United States is increasing because of effective treatments and improved survival. The purpose of this study was to use a national, population-based sample to estimate the burden of illness in adult survivors of childhood cancer. METHODS A total of 410 adult survivors of childhood cancer and 294,641 individuals without cancer were identified from multiple years of the National Health Interview Survey. Multiple measures of burden, general health, and lost productivity were compared using multivariate regression analyses including: logistic, polytomous logit, proportional odds, and linear models. RESULTS Controlling for the effects of age, sex, race/ethnicity, and survey year, adult survivors of childhood cancer reported poorer outcomes across the majority of general health measures and productivity measures than individuals without cancer. Survivors were more likely to report their health status as fair or poor (24.3% vs 10.9%; P<.001); having any health limitation in any way (12.9% vs 3.4%; P<.001); being unable to work because of health problems (20.9% vs 6.3%; P<.001); and being limited in the amount/kind of work because of health problems (30.9% vs 10.6%; P<.001). When categorized by time since diagnosis, cancer survivors had poor health outcomes in every time interval, with the greatest limitations in the initial 4 years after diagnosis and 30 or more years after diagnosis. CONCLUSIONS Across multiple measures, adult survivors of childhood cancers have poorer health outcomes and more health limitations than similar individuals without cancer.
Collapse
Affiliation(s)
- Emily Dowling
- Applied Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-7344, USA.
| | | | | | | | | | | |
Collapse
|
85
|
Friedman DL, Whitton J, Leisenring W, Mertens AC, Hammond S, Stovall M, Donaldson SS, Meadows AT, Robison LL, Neglia JP. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 2010; 102:1083-95. [PMID: 20634481 DOI: 10.1093/jnci/djq238] [Citation(s) in RCA: 482] [Impact Index Per Article: 34.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
BACKGROUND The occurrence of subsequent neoplasms has direct impact on the quantity and quality of life in cancer survivors. We have expanded our analysis of these events in the Childhood Cancer Survivor Study (CCSS) to better understand the occurrence of these events as the survivor population ages. METHODS The incidence of and risk for subsequent neoplasms occurring 5 years or more after the childhood cancer diagnosis were determined among 14,359 5-year survivors in the CCSS who were treated from 1970 through 1986 and who were at a median age of 30 years (range = 5-56 years) for this analysis. At 30 years after childhood cancer diagnosis, we calculated cumulative incidence at 30 years of subsequent neoplasms and calculated standardized incidence ratios (SIRs), excess absolute risks (EARs) for invasive second malignant neoplasms, and relative risks for subsequent neoplasms by use of multivariable Poisson regression. RESULTS Among 14,359 5-year survivors, 1402 subsequently developed 2703 neoplasms. Cumulative incidence at 30 years after the childhood cancer diagnosis was 20.5% (95% confidence interval [CI] = 19.1% to 21.8%) for all subsequent neoplasms, 7.9% (95% CI = 7.2% to 8.5%) for second malignant neoplasms (excluding nonmelanoma skin cancer), 9.1% (95% CI = 8.1% to 10.1%) for nonmelanoma skin cancer, and 3.1% (95% CI = 2.5% to 3.8%) for meningioma. Excess risk was evident for all primary diagnoses (EAR = 2.6 per 1000 person-years, 95% CI = 2.4 to 2.9 per 1000 person-years; SIR = 6.0, 95% CI = 5.5 to 6.4), with the highest being for Hodgkin lymphoma (SIR = 8.7, 95% CI = 7.7 to 9.8) and Ewing sarcoma (SIR = 8.5, 95% CI = 6.2 to 11.7). In the Poisson multivariable analysis, female sex, older age at diagnosis, earlier treatment era, diagnosis of Hodgkin lymphoma, and treatment with radiation therapy were associated with increased risk of subsequent neoplasm. CONCLUSIONS As childhood cancer survivors progress through adulthood, risk of subsequent neoplasms increases. Patients surviving Hodgkin lymphoma are at greatest risk. There is no evidence of risk reduction with increasing duration of follow-up.
Collapse
Affiliation(s)
- Debra L Friedman
- Vanderbilt-Ingram Cancer Center, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
86
|
Henderson TO, Friedman DL, Meadows AT. Childhood cancer survivors: transition to adult-focused risk-based care. Pediatrics 2010; 126:129-36. [PMID: 20547645 DOI: 10.1542/peds.2009-2802] [Citation(s) in RCA: 119] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
BACKGROUND The issues involved in transition from pediatric cancer care to adult-focused care differ from those in other childhood diseases, because malignant disease itself is no longer a problem. However, the potential for fatal outcome places a greater dependence on the pediatric oncology setting and delays this transition process, often beyond adolescence. Adverse long-term physical and psychological effects accompany survival for many of the cured children, and because these effects may not become manifest until adulthood, programs that support transition for childhood cancer survivors require the expertise of many subspecialists. OBJECTIVES To describe the issues and barriers to successful transition programs for childhood cancer survivors when they are ready for adult-focused care. METHODS We reviewed the literature and discuss the barriers to transition at the survivor, provider, and health care system levels for survivors of childhood cancer. We also critically assess the elements of successful transition programs. RESULTS Education of survivors and providers regarding long-term health risks is necessary for a successful transition. This process should be gradual to address the educational needs of survivors, families, and health care professionals, determine "readiness" for transition, and address financial and insurance concerns. Because little is known regarding adverse long-term health-related sequelae beyond the fourth decade of life, research is needed to quantify and reduce the consequences of these morbidities. CONCLUSIONS Transition programs for pediatric cancer survivors require experts who are knowledgeable regarding the long-term follow-up needs of childhood cancer survivors and who can provide a bridge between pediatric oncology and primary care that is risk based.
Collapse
Affiliation(s)
- Tara O Henderson
- Section of Hematology, Oncology and Stem Cell Transplantation, Department of Pediatrics, University of Chicago, Chicago, IL 60637, USA.
| | | | | |
Collapse
|
87
|
Inconsistent mammography perceptions and practices among women at risk of breast cancer following a pediatric malignancy: a report from the Childhood Cancer Survivor Study. Cancer Causes Control 2010; 21:1585-95. [PMID: 20506037 DOI: 10.1007/s10552-010-9587-5] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2010] [Accepted: 05/15/2010] [Indexed: 01/19/2023]
Abstract
Women treated with chest radiation for a pediatric cancer have low mammography screening rates despite their high risk for breast cancer. This study characterized the relationship between perceptions of mammography and screening practices. A cross-sectional survey was administered to 523 women in North America who were treated with chest radiation before 21 years of age. Women with inconsistent mammography perceptions and practices were identified using the Pros and Cons of Mammography for perceptions and Transtheoretical Model stages of adoption for prior and intended screening practices. Classification and regression tree (CART) analysis was used to identify barriers to and facilitators of screening among women with positive and negative perceptions. Nearly one-third of the cohort had inconsistent perceptions and practices: 37.4% had positive perceptions and were not having mammograms; 27.6% had negative/neutral perceptions and were having mammograms. Regardless of perceptions, a recent physician's recommendation for mammography, age ≥ 40, and interest in routine health care were universally associated with mammography practices. For women with positive perceptions and a physician's recommendation, barriers to screening included high acceptance coping, low active-planning coping, and high internal health locus of control. For women with negative perceptions, acknowledging the importance of asymptomatic screening was associated with mammography.
Collapse
|
88
|
Hodgson DC, Grunfeld E, Gunraj N, Del Giudice L. A population-based study of follow-up care for Hodgkin lymphoma survivors. Cancer 2010; 116:3417-25. [DOI: 10.1002/cncr.25053] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
89
|
Henderson TO, Amsterdam A, Bhatia S, Hudson MM, Meadows AT, Neglia JP, Diller LR, Constine LS, Smith RA, Mahoney MC, Morris EA, Montgomery LL, Landier W, Smith SM, Robison LL, Oeffinger KC. Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. Ann Intern Med 2010. [PMID: 20368650 DOI: 10.1059/0003-4819-152-7-201004060-00009] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
BACKGROUND Women treated with therapeutic chest radiation may develop breast cancer. PURPOSE To summarize breast cancer risk and breast cancer surveillance in women after chest radiation for pediatric or young adult cancer. DATA SOURCES Studies from MEDLINE, EMBASE, the Cochrane Library, and CINAHL (1966 to December 2008). STUDY SELECTION Articles were selected to answer any of 3 questions: What is the incidence and excess risk for breast cancer in women after chest radiation for pediatric or young adult cancer? For these women, are the clinical characteristics of breast cancer and the outcomes after therapy different from those of women with sporadic breast cancer in the general population? What are the potential benefits and harms associated with breast cancer surveillance among women exposed to chest radiation? DATA EXTRACTION Three investigators independently extracted data and assessed study quality. DATA SYNTHESIS Standardized incidence ratios ranged from 13.3 to 55.5; cumulative incidence of breast cancer by age 40 to 45 years ranged from 13% to 20%. Risk for breast cancer increased linearly with chest radiation dose. Available limited evidence suggests that the characteristics of breast cancer in these women and the outcomes after diagnosis are similar to those of women in the general population; mammography can detect breast cancer, although sensitivity is limited. LIMITATION The quality of evidence for key questions 2 and 3 is limited by substantial study heterogeneity, variation in study design, and small sample size. CONCLUSION Women treated with chest radiation have a substantially elevated risk for breast cancer at a young age, which does not seem to plateau. In this high-risk population, there seems to be a benefit associated with early detection. Further research is required to better define the harms and benefits of lifelong surveillance.
Collapse
Affiliation(s)
- Tara O Henderson
- University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
90
|
Henderson TO, Amsterdam A, Bhatia S, Hudson MM, Meadows AT, Neglia JP, Diller LR, Constine LS, Smith RA, Mahoney MC, Morris EA, Montgomery LL, Landier W, Smith SM, Robison LL, Oeffinger KC. Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. Ann Intern Med 2010; 152:444-55; W144-54. [PMID: 20368650 PMCID: PMC2857928 DOI: 10.7326/0003-4819-152-7-201004060-00009] [Citation(s) in RCA: 166] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND Women treated with therapeutic chest radiation may develop breast cancer. PURPOSE To summarize breast cancer risk and breast cancer surveillance in women after chest radiation for pediatric or young adult cancer. DATA SOURCES Studies from MEDLINE, EMBASE, the Cochrane Library, and CINAHL (1966 to December 2008). STUDY SELECTION Articles were selected to answer any of 3 questions: What is the incidence and excess risk for breast cancer in women after chest radiation for pediatric or young adult cancer? For these women, are the clinical characteristics of breast cancer and the outcomes after therapy different from those of women with sporadic breast cancer in the general population? What are the potential benefits and harms associated with breast cancer surveillance among women exposed to chest radiation? DATA EXTRACTION Three investigators independently extracted data and assessed study quality. DATA SYNTHESIS Standardized incidence ratios ranged from 13.3 to 55.5; cumulative incidence of breast cancer by age 40 to 45 years ranged from 13% to 20%. Risk for breast cancer increased linearly with chest radiation dose. Available limited evidence suggests that the characteristics of breast cancer in these women and the outcomes after diagnosis are similar to those of women in the general population; mammography can detect breast cancer, although sensitivity is limited. LIMITATION The quality of evidence for key questions 2 and 3 is limited by substantial study heterogeneity, variation in study design, and small sample size. CONCLUSION Women treated with chest radiation have a substantially elevated risk for breast cancer at a young age, which does not seem to plateau. In this high-risk population, there seems to be a benefit associated with early detection. Further research is required to better define the harms and benefits of lifelong surveillance.
Collapse
Affiliation(s)
- Tara O Henderson
- University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
91
|
Freyer DR. Transition of care for young adult survivors of childhood and adolescent cancer: rationale and approaches. J Clin Oncol 2010; 28:4810-8. [PMID: 20351333 DOI: 10.1200/jco.2009.23.4278] [Citation(s) in RCA: 126] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE Young adult survivors of childhood and adolescent cancer are an ever-growing population of patients, many of whom remain at lifelong risk for potentially serious complications of their cancer therapy. Yet research shows that many of these older survivors have deficient health-related knowledge and are not engaging in recommended health promotion and screening practices that could improve their long-term outcomes. The purpose of this review is to address these disparities by discussing how formal transition of care from pediatric to adult-focused survivorship services may help meet the unique medical, developmental, and psychosocial challenges of these young adults. DESIGN Literature review and discussion. RESULTS This article summarizes current research documenting the medical needs of young adult survivors, their suboptimal compliance with recommended follow-up, and the rationale, essential functions, current models, and innovative approaches for transition of follow-up care. CONCLUSION Systematic health care transition constitutes the standard of care for young adult survivors of childhood cancer. In developing a transitional care program, it is necessary to consider the scope of services to be provided, available resources, and other local exigencies that help determine the optimal model for use. Additional research is needed to improve health services delivery to this population. Effective advocacy is needed, particularly in the United States, to ensure the availability of uninterrupted health insurance coverage for survivorship services in young adulthood.
Collapse
Affiliation(s)
- David R Freyer
- LIFE Survivorship and Transition Program, Childrens Center for Cancer and Blood Diseases, Childrens Hospital Los Angeles, and Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
| |
Collapse
|
92
|
Cancer screening and preventative care among long-term cancer survivors in the United Kingdom. Br J Cancer 2010; 102:1085-90. [PMID: 20234361 PMCID: PMC2853098 DOI: 10.1038/sj.bjc.6605609] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
Background: Long-term cancer survivors in the United Kingdom are mostly followed up in a primary care setting by their general practitioner; however, there is little research on the use of services. This study examines whether cancer survivors receive adequate screening and preventative care in UK primary care. Patients and methods: We identified a cohort of long-term survivors of breast, colorectal and prostate cancer with at least a 5-year survival using the General Practice Research Database, with controls matched for age, gender and practice. We compared adherence with cancer screening and the use of preventative care between cancer survivors and controls. Results: The cancer survivors’ cohort consisted of 18 612 breast, 5764 colorectal and 4868 prostate cancer survivors. Most cancer survivors receive cancer screening at the same levels as controls, except for breast cancer survivors who were less likely to receive a mammogram than controls (OR=0.78, 95% CI: 0.66–0.92). Long-term cancer survivors received comparable levels of influenza vaccinations and cholesterol tests, but breast (OR 0.81, 95% CI: 0.74–0.87) and prostate cancer survivors (OR=0.70, 95% CI: 0.57–0.87) were less likely to receive a blood pressure test. All survivors were more likely to receive bone densitometry. Conclusion: The provision and uptake of preventive care in a primary care setting in the United Kingdom is comparable between the survivors of three common cancers and those who have not had cancer. However, long-term breast cancer survivors in this cohort were less likely to receive a mammogram.
Collapse
|
93
|
Abstract
Late effects of therapy for childhood cancer are frequent and serious. Fortunately, many late effects are also modifiable. Proactive and anticipatory risk-based care can reduce the frequency and severity of treatment-related morbidity. The primary care clinician should be an integral component in risk-based care of survivors. Continued communication between the "late effects" staff at the cancer center and the primary care clinician is essential for optimum care of this high-risk population.
Collapse
Affiliation(s)
- Kevin C Oeffinger
- Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
| | | | | |
Collapse
|
94
|
Colditz GA. Ensuring long-term sustainability of existing cohorts remains the highest priority to inform cancer prevention and control. Cancer Causes Control 2010; 21:649-56. [PMID: 20063074 PMCID: PMC2855811 DOI: 10.1007/s10552-009-9498-5] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2009] [Accepted: 12/23/2009] [Indexed: 11/28/2022]
Abstract
The case for continued follow-up of existing cohorts arises from the key attributes of cohorts that are already meeting the goals proposed by Potter for the creation of a new cohort. These attributes include the basic nature of ongoing cohorts in that they are, by design, hypothesis-driven and must adapt to emerging technologies over time. Importantly, cohort investigators must identify and address gaps in knowledge that will inform public health strategies and clinical practices. Above all, cohorts must capitalize on their unique features to address public health priorities and inform our prevention strategies. Continued follow-up adds substantial return on investment to guide cancer prevention.
Collapse
Affiliation(s)
- Graham A. Colditz
- Institute For Public Health, Washington University In St Louis, St. Louis, MO 63110 USA
| |
Collapse
|
95
|
Henderson TO, Hlubocky FJ, Wroblewski KE, Diller L, Daugherty CK. Physician preferences and knowledge gaps regarding the care of childhood cancer survivors: a mailed survey of pediatric oncologists. J Clin Oncol 2009; 28:878-83. [PMID: 20038717 DOI: 10.1200/jco.2009.25.6107] [Citation(s) in RCA: 69] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE Little is known about physicians' attitudes and knowledge regarding the health care needs of childhood cancer survivors (CCS). We sought to obtain pediatric cancer physicians' self-reported attitudes and knowledge regarding this population. METHODS A mailed survey was sent to 1,159 pediatric oncologists in the United States. Results A total of 655 surveys were returned (ie, 57% response rate). Median age of respondents was 47 years (range, 31 to 82 years); 57% were men. Respondents practiced for a median 14 years (range, 1 to 50 years) and reported seeing a median of 21 patients per week (range, 0 to 250 patients per week). When comfort levels in caring for CCS were described (ie, 1 = very uncomfortable; 7 = very comfortable), respondents were most comfortable with survivors < or = 21 years (mean +/- standard deviation, 6.2 +/- 1.3 level), were less comfortable (5.0 +/- 1.5 level) with those older than 21 years but less than 30 years old, and were uncomfortable with CCS > or = 30 years (2.9 +/- 1.7 level). In response to a clinical vignette of a 29-year-old woman treated with mantle radiation for Hodgkin's lymphoma at 16 years of age, and on the basis of available guidelines, 34% of respondents did not appropriately recommend yearly breast cancer surveillance; 43% of respondents did not appropriately recommend cardiac surveillance; and 24% of respondents did not appropriately recommend yearly thyroid surveillance. Those with greater self-reported familiarity with available long-term follow-up (LTFU) guidelines (odds ratio [OR], 1.33; 95% CI, 1.15 to 1.54) and with receipt of training in the care of CCS (OR, 1.73; 95% CI, 1.18 to 2.52) were more likely to have answered all three questions correctly. CONCLUSION Pediatric oncologists express a range of preferences with regard to LTFU of CCS. Many appear unfamiliar with LTFU surveillance guidelines.
Collapse
Affiliation(s)
- Tara O Henderson
- University of Chicago, Section of Pediatric Hematology, Oncology and Stem Cell Transplantation, 5841 S Maryland Ave, MC 4060, Chicago, IL 60637, USA.
| | | | | | | | | |
Collapse
|
96
|
Affiliation(s)
- Kevin C Oeffinger
- Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
| | | |
Collapse
|
97
|
Beatty JS, Williams HT, Gucwa AL, Hughes MP, Vasudeva VS, Aldridge BA, Fields DM, David GS, Lind DS, Kruse EJ, McLoughlin JM. The predictive value of incidental PET/CT findings suspicious for breast cancer in women with non-breast malignancies. Am J Surg 2009; 198:495-9. [DOI: 10.1016/j.amjsurg.2009.06.009] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2009] [Revised: 06/14/2009] [Accepted: 06/14/2009] [Indexed: 11/27/2022]
|
98
|
Robison LL, Armstrong GT, Boice JD, Chow EJ, Davies SM, Donaldson SS, Green DM, Hammond S, Meadows AT, Mertens AC, Mulvihill JJ, Nathan PC, Neglia JP, Packer RJ, Rajaraman P, Sklar CA, Stovall M, Strong LC, Yasui Y, Zeltzer LK. The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research. J Clin Oncol 2009; 27:2308-18. [PMID: 19364948 DOI: 10.1200/jco.2009.22.3339] [Citation(s) in RCA: 509] [Impact Index Per Article: 33.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
Survival for childhood cancer has increased dramatically over the last 40 years with 5-year survival rates now approaching 80%. For many diagnostic groups, rapid increases in survival began in the 1970s with the broader introduction of multimodality approaches, often including combination chemotherapy with or without radiation therapy. With this increase in rates of survivorship has come the recognition that survivors are at risk for adverse health and quality-of-life outcomes, with risk being influenced by host-, disease-, and treatment-related factors. In 1994, the US National Cancer Institute funded the Childhood Cancer Survivor Study, a multi-institutional research initiative designed to establish a large and extensively characterized cohort of more than 14,000 5-year survivors of childhood and adolescent cancer diagnosed between 1970 and 1986. This ongoing study, which reflects the single most comprehensive body of information ever assembled on childhood and adolescent cancer survivors, provides a dynamic framework and resource to investigate current and future questions about childhood cancer survivors.
Collapse
Affiliation(s)
- Leslie L Robison
- Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN 38105-2794, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|